| 000 | 01604 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514000828.0 | ||
| 264 | 0 | _c20011101 | |
| 008 | 200111s 0 0 eng d | ||
| 022 | _a0091-2700 | ||
| 024 | 7 |
_a10.1177/00912700122010401 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCass, L M | |
| 245 | 0 | 0 |
_aThe bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _cMay 2001 |
||
| 300 |
_a528-35 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aConfidence Intervals |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDietary Fats |
| 650 | 0 | 4 | _aFood-Drug Interactions |
| 650 | 0 | 4 |
_aGastrointestinal Diseases _xchemically induced |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHeadache _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLeast-Squares Analysis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aQuinoxalines _xadverse effects |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xadverse effects |
| 700 | 1 | _aMoore, K H | |
| 700 | 1 | _aDallow, N S | |
| 700 | 1 | _aJones, A E | |
| 700 | 1 | _aSisson, J R | |
| 700 | 1 | _aPrince, W T | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 41 _gno. 5 _gp. 528-35 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/00912700122010401 _zAvailable from publisher's website |
| 999 |
_c11293057 _d11293057 |
||